Clin Pharmacol Ther 111(1):272282 Ueda P, Wintzell V, Melbye M, Eliasson B, Sderling J, Gudbjrnsdottir S, Pasternak B (2023) Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study
We assess injury history, inflammation patterns, gut health, metabolic status and overall medical background to determine whether peptide therapy such as GHK-Cu or other regenerative peptides is appropriate
Body contouring procedures are common in people taking semaglutide or other GLP-1s, as they move forward on their weight loss journey
Acknowledgements We gratefully acknowledge the valuable cooperation of Huiping Ma (Center of Animal Experiment, Chinese Peoples Liberation Army Joint Logistic Support Force 940th Hospital) in preparing this animal model experiment